The European Medicines Agency is preparing new EU guidance for companies and regulators on the development and manufacture of synthetic oligonucleotides and synthetic peptides for use as medicines.
Guidance is needed because the number of clinical trial and marketing authorization applications for each kind of product has increased...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?